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Abstract
Background: The medical care of malaria is a clinical emergency because it may develop into severe malaria,
which has a high risk of complications and death. One of the major complications of Plasmodium falciparum
infections is cerebral malaria (CM), which is responsible for at least 175,000 deaths worldwide each year and has
long-term neurological sequelae. Moreover, treatment for CM is only partially effective. Statins are now known
to have anti-inflammatory action, to attenuate sepsis and to have neuroprotective effects. In vitro, atorvastatin
(AVA) has an anti-malarial activity and has improved the activity of quinine (QN), mefloquine (MQ), and
dihydroartemisinin (DHA).
Objectives: This study had two objectives. First, the ability of AVA to enhance DHA efficacy by improving the
survival rate for CM and also decreasing signs of CM was evaluated in a murine model of experimental cerebral
malaria (ECM), which was designed in C57BL6/N mice. Second, the inflammatory biomarkers were assessed at D6
and D10 in mice treated by DHA and in untreated mice in which clinical signs of CM appear rapidly and death
occurs before D12. Both experiments were designed with seven days of treatment with 40 mg/kg AVA combined
with five days of 3 mg/kg DHA administered intraperitoneally.
Results: AVA in combination with DHA in a therapeutic scheme leads to a significant delay in mouse death, and it
has an effect on the onset of CM symptoms and on the level of parasitaemia. Evaluation of the biomarkers
highlights the significant difference between treated and control mice for five cytokines and chemokines
(Eotaxin-CCL11, IL-13, LIX-CXCL5, MIP1b-CCL4 and MIP2) that are known to have a role in chemotaxis.
Conclusions: The combination of DHA and AVA seems to be effective as a therapeutic scheme for improving
mouse survival but less effective for cytokine modulation, which is associated with protection against CM. These
results call for clinical trials of AVA as an adjuvant with anti-malarial therapy, especially with artemisinin-based
combination therapy, in CM treatment or prevention.
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Background
In 2002, the World Health Organization (WHO) recom-
mended that artemisinin-based combination therapy (ACT)
be used for all cases of uncomplicated malaria. Four years
later, the WHO added the recommendation that artesunate
be deployed as the first-line treatment for severe malaria
in adults and that it replace quinine because of its higher
efficacy and better tolerance [1]. In 2010, a large-scale trial
confirmed the effectiveness of artesunate in the treatment
of severe malaria in children [2]. In 2011, the WHO
recommended artesunate as the first-line treatment for
severe malaria. In recent years, several studies have
reported clinical failures, or at least extended parasite
clearance times, in Cambodia [3-5]. In 2010, quinine
remained widely used, especially in Africa, for severe
malaria [6], and a number of studies have since been
carried out to increase the effectiveness of quinine,
seeking drug interactions that enhance anti-malarial
effect [7,8].
A great scientific effort is aimed at elucidating the
mechanisms underlying the resistance to anti-malarial
drugs, with the hope of restoring and improving the
efficacy of existing drugs and developing new drugs
that can bypass the resistance mechanisms. One of the
strategies that has been used to reduce the prevalence
of malaria is the use of drug combinations. Using a
combination of drugs prevents resistance to each drug
from developing and thus reduces the overall transmis-
sion rate of malaria [9]. There is an urgent need for the
discovery of suitable drug combinations with artemisinin
derivatives.
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-Co-
enzyme A reductase (HMG-CoA reductase), are a family of
lipid-lowering drugs that have recently been demonstrated
to have in vitro anti-malarial properties [10,11]. Moreover,
atorvastatin (AVA) improved the in vitro activity of meflo-
quine (MQ) [12], quinine (QN) [13] or dihydroartemisinin
(DHA) [14] at plasma concentrations expected in clinical
observations for patients taking 80 mg of AVA daily (0.1
to 0.5 μM) [15]. Nevertheless, AVA, used alone, failed to
prevent death from cerebral malaria (CM) or to affect the
parasitaemia of infected mice [16]. AVA combined with
MQ led to a significant delay in mouse death and affected
on the onset of CM symptoms [17].
The objective of the present work was to evaluate the
in vivo efficacy of AVA with DHA or QN, the two anti-
malarial drugs recommended for severe malaria that have
in vitro synergy when combined with AVA, in a murine
model of experimental cerebral malaria (ECM). The doses
of DHA or QN used in the present study were relevant
with clinical and with plasma concentrations expected in
clinical observations for patients. Animal models do not
exactly reproduce human malaria, but they nevertheless
exhibit some similarities to human CM, and the use of the
Plasmodium berghei ANKA rodent parasite model is
generally accepted as one of the valid models for studying
ECM pathogenesis [18,19].
Methods
Mice
All animals were pathogen free and were housed under
standard conditions, with unlimited access to food and
water. All efforts were made to minimize animal suffering.
All experiments adhered to French guidelines for animal
research and were approved by the ethics committee of the
Institut de Recherche Biomédicale des Armées-Antenne de
Marseille (Number 2007–08).
Experimental cerebral malaria and biomarker
levels analysis
Ninety (for experimental cerebral malaria) and sixty (for
biomarker levels analysis) female C57Bl6/Nmice, 6–7 weeks
old and weighting 18–22 g (Charles Rivers, France), were
infected on day 0 (D0) with P. berghei ANKA by intraperi-
toneal (i.p.) inoculation of 105 parasitized erythrocytes in
200 μL from infected donor C57Bl6/N mice, diluted in
normal saline solution.
Drug and therapy protocol
AVA calcium salt was purchased from Molekula (UK),
and QN and DHA were obtained from Sigma (St Louis,
MO, USA). QN and DHA were dissolved in normal saline
solution. AVA was dissolved in dimethyl sulfoxide (DMSO)
1% (v/v) in NaCl 0.9% at 20 or 40 mg/kg. The AVA
solutions were sonicated (Bioblock Scientific/Ultrasonic
Processors-VCX 600 W) for 5 minutes on ice (4°C) at 75%
amplitude with 5 seconds on pulse and 10 seconds on
pause.
Dihydroartemisinin-atorvastatin combination
When parasitaemia was about 0.5%, the mice were treated
by i.p. injection with 3 mg/kg DHA alone for 5 days,
40 mg/kg AVA alone for 7 days or the combination, 3 mg/
kg DHA (5 days) and 40 mg/kg AVA (7 days). Control
mice were treated with NaCl 0.9% only.
Quinine-atorvastatin combination
When parasitaemia was about 0.5%, the mice were treated
by i.p. injection with 40 mg/kg QN alone for 7 days,
40 mg/kg AVA alone for 7 days or 40 mg/kg QN combined
with 40 mg/kg AVA (high dose) or 20 mg/kg AVA
(low dose) for 7 days. Control mice were treated with
NaCl 0.9% only.
Parasitemia and clinical parameters
Parasitemia was determined daily using Giemsa-stained
thin blood smears collected from the tail vein, by assessing
the number of infected red blood cells based on 3,000
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erythrocytes if > 1% were infected and based on 10,000
erythrocytes if < 1% were infected (1.9 to 2.9%). The
animals were under daily supervision for clinical signs,
neurological symptoms and weight. ECM was diagnosed
by clinical signs based on a simplified SHIRPA protocol
[20] with at least two symptoms in at least two of the three
different groups: 1) alteration of autonomous function
(piloerection, defecation, urination, respiration rate); 2)
alteration of muscle tone and strength (grip strength,
body tone, limb tone, abdominal tone); and 3) ataxia,
paralysis (mono-, hemi-, para-, or tetraplegia), deviation
of the head, convulsions and coma.
Multiplexed microsphere cytokine immunoassay
Serum (50 μL) from the control (CT), AVA, DHA and
DHA combined with AVA (DHA + AVA) groups was
evaluated for 32 circulating cytokines simultaneously
(Eotaxin, G-CSF, GM-CSF, IFN γ, IL-1α, IL-1β, IL-10,
IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX-CXCL5,
MCP-1, M-CSF, MIG, MIP1-CCL3, MIP1β-CCL4, MIP-2,
RANTES, TNF, and VEGF) using a multiplex bead-based
cytokine immunoassay coupled with the Luminex200 ™
system (Biorad) and mouse-specific bead sets from the
MILLIPLEX ™ MAP mouse cytokine/chemokine kit 32
Wells Plate Assay (MCYTMAG-70 K-PX32-Millipore,
Belford, MA, USA), according to the manufacturer’s
instructions. The results were interpolated using a five-
parameter logistic method. Samples were tested at a 1:1
dilution.
Statistical analyses
All statistical analyses were performed with R software
(version 2.10.1). Survival analyses were performed by
Kaplan-Meier log rank test. Box plot graphs outlined the
25th and 75th percentiles and the median, with bars
representing the minimum and maximum. Box plot graphs
were made with GraphPad Prism 5 software (version 5.01),
and P-values < 0.05 indicate a significant difference.
Results
Effects of the dihydroartemisinin/atorvastatin
combination on mortality in ECM
For the curative treatment, there was a significant differ-
ence (P = 0.0029) in survival between untreated mice and
mice treated with a 3 mg/kg dose of DHA or the combin-
ation of DHA with 40 mg/kg AVA. In the CT group, all
mice died before D10 with specific signs of CM and with
parasitaemia < 10% (5.2 to 10%) (Figure 1). In the AVA
group, more than half of the mice died before D5 with
specific signs of CM and with parasitaemia < 10% (4.8 to
8.8%). The last four mice died at D10, D21, D22, and D23
with 19%, 85%, 74% and 67% parasitaemia, respectively.
AVA alone is ineffective against P. berghei, and there was
no significant difference between the CT and AVA groups
(P = 0.283). The mice treated with 3 mg/kg DHA died
between D2 and D27 (parasitaemia from 1.3 to 84%).
During the 5 days of treatment, parasitaemia remained
low (0.4% on D3); however, after these 5 days of treatment,
parasitaemia increased to 1.9%. There was no death before
D10 in the group of mice treated with 3 mg/kg DHA
combined with 40 mg/kg AVA. After 5 days of treatment
with 3 mg/kg DHA combined with 7 days of treatment
with 40 mg/kg AVA, parasitaemia decreased to 0.4%
before it started to increase (Figure 2). The remaining
mice died between D15 and D26, with parasitaemia that
ranged from 11 to 84%.
Treatments with DHA and the combination of AVA
and DHA were significantly effective for CM treatment
(P ≤ 0.05 and P ≤ 0.005, respectively). However, for mice
treated with DHA alone, half of the mice died not only
with 80% of the specific signs of CM but also with
parasitaemia that ranged between 3.5% and 7% from
D2 to D11. After D11, the mice died from anaemia with
parasitaemia that ranged from 39.8% to 91%, and by D23,
all the mice were dead. The combination of DHA and
AVA was more effective than DHA alone in the murine
model of ECM (P < 0.05) for the first two weeks (D15)
after the appearance of P. berghei in red blood cells. The
analyses showed that, after these two weeks, the effects of
this combination were not significant (P = 0.6). It seems
that the efficacy of the combination is due to synergy
between the two compounds, as there was a significant
difference between the efficacy of DHA alone and that
of the combination of AVA and DHA (P = 0.028).
Effects of the quinine/atorvastatin combination
on mortality in ECM
In the curative treatment, there was a significant difference
(P = 1.1e-8) in survival between untreated mice and mice
treated with a 40 mg/kg dose of QN or the combination of
QN with 40 mg/kg AVA or 20 mg/kg AVA. In the control
group, all of the mice died at D7 with specific signs of
CM and parasitaemia that ranged from 16.5% to 46.7%
(mean = 40.6%) (Figure 3). The mice treated with the
40 mg/kg dose of QN died between D12 and D22.
After 7 days of treatment with the 40 mg/kg dose of
QN, parasitaemia increased to between 18% and 52%
(mean = 40%) at D12, at which point the mice died
without specific signs of CM but with the same level of
parasitaemia as that of the control group. Meanwhile,
one mouse (25%) died at D13 and one mouse died at
D22, with 28.8 and 91% parasitaemia, respectively.
In the group of mice treated with 40 mg/kg QN com-
bined with 40 mg/kg AVA, mice did not survive longer
and died from cerebral malaria at D12, with parasitaemia
that ranged from 26.6% to 42.7%. In all, 75% of mice
treated with 40 mg/kg QN combined with 20 mg/kg
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AVA died at D12, with parasitaemia that ranged from
30.2 to 55.9% (mean = 39.8%) but also without specific
signs of CM. The remaining 25% of the mice died at D15
and D23, with 32.3% and 98% parasitaemia, respectively
(Figure 4). Meanwhile, there was no significant difference
between the two doses of AVA used in combination with
quinine (P = 0.202).
Biomarker levels in the different mice groups
The parasitaemia levels were similar in the CT, AVA, DHA
and DHA+AVA groups at D6 (0.1 to 0.5%). To analyse the
biomarker concentration, five mice in each group were
euthanized, and sera were collected at D6 and D10. Only
five cytokines and chemokines were identified from the
analysis, with P < 0.05 (Figure 5).
At day 6, some biomarkers had variations; for example,
eotaxin/CCL11 had a significant increase in the DHA
group versus the CT group (P = 7.9e-3), but in the DHA +
AVA group, it had a significantly lower concentration
(P = 1.59e-2) compared to the CT group. Additionally,
the concentration of IL-23 was significantly lower in the
DHA + AVA group when compared to the CT group
(P = 1.59e-2). In contrast to Eotaxin/CCL11, MIP2 was
down-regulated in the DHA group (P = 5.71e-2) but
was up-regulated in the DHA + AVA group.
At day 10, three biomarkers were detected with the
only significant difference being between the CT and
DHA + AVA groups. Eotaxin/CCL11 and LIX-CXCL5
were found to be highly regulated with P = 7.9e-3 and
P = 1.59e-2, respectively, although MIP1 β-CCL4 had a
lower concentration in the DHA+AVA group (P = 7.9e-3).
Discussion
The present results demonstrate that, in an in vivo ECM
model, AVA improved the therapeutic effects of DHA
but not those of QN. In a therapeutic i.p scheme, the
combination of AVA and DHA versus DHA alone resulted
in a significant delay in mouse death and had an effect on
the onset of CM symptoms and on the level of parasit-
aemia. The experimental conditions did not prevent death,
Figure 1 Survival curve of C57BL6/N mice infected on day 0 (D0) with P. berghei ANKA parasites and treated with 3 mg/kg
dihydroartemisinin (five days), 40 mg/kg atorvastatin (seven days) or 3 mg/kg dihydroartemisinin combined with 40 mg/kg
atorvastatin for five and seven days, respectively.
Figure 2 Parasitemia in dihydroartemisinin and atorvastatin assay for the control group, 3 mg/kg dihydroartemisinin (five days),
40 mg/kg atorvastatin (seven days) or 3 mg/kg dihydroartemisinin combined with 40 mg/kg atorvastatin for five and seven
days, respectively.
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but it seemed that the mice of the combination group did
not die of CM, as the mice in the other groups did, but
rather died of anaemia with high parasitaemia. As shown
previously, AVA, like other statins, is not effective alone
as a treatment for severe malaria [21,22]. Even if AVA
improved the in vitro activity of DHA [14], QN [13] or
MQ [12], AVA acts differently in an in vivo combination
with these three anti-malarial drugs. AVA significantly
delays mouse death by CM and inhibits the development
of CM symptoms when combined with anti-malarial
drugs that, alone, had little or no effect in our ECM
model, such as DHA (50% of the mice died with specific
CM symptoms) or MQ, as previously described [17]. AVA
does not improve the efficacy of anti-malarial drugs that
have a significant effect when used alone, such as QN (no
death with specific symptoms of CM). The pathogenesis
of CM in the murine model relies solely on the inflamma-
tory response, unlike the pathogenesis of human CM.
Indeed, the cytoadherence phenomenon does not exist
in P. berghei mouse infections [20,23,24]. AVA showed
the ability to strongly protect endothelial cells against
P. falciparum-induced collateral damage, such as cell
apoptosis and endothelial barrier permeabilization [23,24].
Additionally, AVA can be used to reduce the cytoadherence
of P. falciparum on endothelial cells, a key event during
infection, along with the inflammatory burst, which is
involved in the pathogenesis of severe human malaria
cases. Moreover, lovastatin decreases neuroinflammation
and prevents cognitive impairment after cerebral malaria
in mice infected with P. berghei ANKA [25].
Obviously, experimental models cannot reproduce all
the features of human diseases. Among the differences
between experimental models and the human disease
are that leucocytes, rather than parasitized red blood
cells, are the main cells sequestered in brain vessels;
parasitized red blood cells lack knobs; and infected mice
do not develop high fever [18]. However, the model
based on C57BL6 mice infected by P. berghei ANKA
shares the main features observed in human CM, with a
clinical picture that includes coma, neurological impair-
ment and a systemic, as well as a local, immune response
[20,26-28]. In the present study, as is usually described,
Figure 3 Survival curve of C57BL6/N mice infected on day 0 (D0) with P. berghei ANKA parasites and treated with 40 mg/kg quinine
(five days), 40 mg/kg atorvastatin (seven days) or 40 mg/kg quinine combined with 40 mg/kg atorvastatin for five and seven
days, respectively.
Figure 4 Parasitemia in dihydroartemisinin and atorvastatin assay for the control group, 40 mg/kg quinine (five days), 40 mg/kg
atorvastatin (seven days) or 40 mg quinine combined with 40 mg/kg atorvastatin for five and seven days, respectively.
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Figure 5 Serum biomarker levels (pg/ml) from D6 and D10. Box plots graphs outline the 25th and 75th percentiles and the median, with
bars representing the minimum and maximum (white colour for CT, light pink for AVA, pink for DHA, red for DHA + AVA).
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death occurred after 8–12 days for 85 to 95% of the mice.
Different host-parasite factors such as genetic background,
age, amount of inocula, course of parasitaemia and clonal
variation of the parasite may also interfere with the inci-
dence of CM and may explain the different evolutions of
parasitaemia in the present experiments [26].
The difference between the DHA +AVA group and the
DHA alone group could be explained by the modulation
of the inflammatory response by AVA. This modulation
may prevent the cytoadherence at concentrations higher
than 0.5 μM of AVA and endothelial damage related to
CM or it may inhibit diapedesis, due to its pleiotropic
effects [29-31]. A dose of 0.5 μM is relevant with plasma
concentrations expected in clinical observations for patients
taking 80 mg of AVA daily [15]. The present work demon-
strated the improvement of the therapeutic effects of
DHA with AVA in CM, in comparison with DHA alone,
and the active metabolite of the anti-malarial drug is
recommended by the WHO as the first-line treatment for
severe malaria. Moreover, the dosage of 3 mg/kg is between
the maximal (3.1 mg/kg) and minimal (1.6 mg/kg) values
recommended for use in patients with uncomplicated or
severe malaria [32].
An advantage for the use of AVA as an adjuvant for
anti-malarial drugs is that AVA is already largely recom-
mended to decrease cardiac morbidity and mortality
[33-36], with a dose and frequency higher than that
used in this ECM protocol. These results confirmed not
only the results of the first in vitro approach that was
carried out with 13 isolates of Plasmodium falciparum
[14], but also the therapeutic potential of the combination
of DHA with AVA in vivo.
In this therapeutic scheme, the combination of DHA
and AVA was administered, with five days of DHA and
seven days of AVA, but the effect of DHA +AVA was
not observed to be significant until D15. Our analysis of
the biomarkers affected by this treatment revealed that
Eotaxin/CCL11 and IL-13 were down-regulated and
that MIP2 was up-regulated in the DHA + AVA group
compared to the CT group at D6. MIP2 is known as a
CXC chemokine that is implicated in the recruitment of
immune cells [37,38], and eotaxin/CCL11 is a cytokine
belonging to the CC chemokine family that selectively
recruits eosinophils by inducing chemotaxis. The effects
of CCL11 are mediated by its binding to a G-protein-
linked receptor known as a chemokine receptor, and it is
able not only to decrease neurogenesis and cognitive
performance [39] but also, with other chemokines, to
induce the migration of circulating fibrocytes in patients
with severe asthma [40]. IL-13 is one of the first mediators
of inflammation and disease, which specifically induces
the physiological changes in parasitized organs that are
required to expel the offending organisms or their products.
At D10, we observed an up-regulation of Eotaxin/CCL11
and LIX-CXCL5 and a down-regulation of MIP1 β-CCL4
in the DHA +AVA group, compared to the CT group.
LIX-CXCL5 is known as a chemokine with angiogenic
properties that stimulates the chemotaxis of neutrophils
[41-43]. MIP1 β-CCL4 was also detected, and this finding
is interesting because it has been demonstrated that a
reduction of the T-cell-chemoattractant chemokines CCL3,
CCL4 and CCL5 leads to cerebral malaria protection in
mice [44], and like the other biomarkers cited above, MIP1
β-CCL4 plays a role in the chemotaxis of immune cells in
during infection [45]. Taken together, these data support
the hypothesis regarding the inhibition of the inflammatory
process involved in CM, and the combination of DHA+
AVA can not only control parasitaemia but also alter the
migration of immune cells. Moreover, AVA can block the
post-translation modifications of G-proteins, indicating
that it can inhibit chemokine receptors, which are also
G-protein-linked receptors, that are involved in inflam-
matory and sepsis events.
The analyses of cytokine data agree with those from
literature, but they also revealed some differences. In mice,
it has been demonstrated that TNF, IFNγ, IL-1, IL-2, IL-6,
IL-10, IL12, IL-18 [46-49] CXCL9 and IP10-CXCL10 are
often detected in ECM [25,46-52]. Indeed, many studies
were carried out to examine the chemokine and cytokine
profiles related to ECM in mice, but this was carried out
with various protocols (anti-malarial drugs injection and
time after infection), and different outcomes were obtained.
In the present model of CM, the immune response was
considered to be a sepsis-like response, prompting
consideration of the biomarkers that could be detected in
the blood. Moreover, the present analysis was conducted
on serum and not on plasma or brain tissue [53,54].
Further experimentation should be carried out to confirm
our hypothesis, such as examination of the biomarkers
detected in the brain.
It is important to place this study in a clinical framework.
CM presents two types of clinical challenges. The first is
that cerebral pathogenesis can be observed quickly without
any relationship between parasitaemia and clinical status
[55,56], which requires prompt case management for
patients. The second type of challenge is that neurologic
impairments are observed among 25% of survivors [57,58],
including musculoskeletal disorder, cognitive trouble and
other sequelae that may disturb life, the ability to work or,
on a greater scale, the economy of a country.
Further studies should be conducted to resolve the solu-
bility of AVA. In this protocol, AVA was i.p. injected. One
of the crucial points among all statin-based experimenta-
tion for malaria is the development of a soluble form, which
should be used for patients in critical status. The only water
soluble statins are pravastatin and rosuvastatin [59].
The combination of DHA and AVA seemed to be
effective as a therapeutic scheme in this survival study, and
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the delay of death in mice treated with this combination
can be explained by the pleiotropic effects of statins on
immune modulation, vascular inflammation, endothelial
function and thrombogenesis. Although the capacity of
statins to strongly modify cytokine and chemokine profiles
is documented [17,49], only five biomarkers were identified
as being associated with this survival modification. Further
studies on this therapeutic treatment scheme are required
to examine whether AVA is a suitable partner for current
malaria drugs.
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